CD8A and neoplasm: Thus, transgenic CD4+ T cells co-expressing class I–restricted tumor antigen–specific TCR and CD8αβ have shown comparable cytotoxic properties to engineered CD8+ T cells and were most potent by activating multiple transcriptional programs associated with enhanced antitumor function.